Mumbai, June 20 -- The new phase, which became operational on 19 June 2025, adds approximately 91 kL of production capacity. This marks the second and final phase of the total planned capacity addition of approximately 195 kL at the facility, as disclosed in the company's prospectus.
With this addition, the total installed capacity at Unit IV now stands at approximately 640 kL. The expanded facility is equipped to manufacture Registered Starting Materials (RSM), intermediates, and Active Pharmaceutical Ingredients (APIs) for both clinical and commercial applications.
Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.